Company Profile

Ibio Inc Stock Price, News & Catalysts

Ticker:
IBIO
Exchange:
AMEX
Sector:
Biopharma
Location:
United States

Stock performance

0.80 USD (-5.55%)

Close

Last updated: November 19, 2026

87.4M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, IBIO closed down 5.55% at $0.8010. No new same-company headline was identified in the current news window.

Company overview

AI-Enabled Antibody Discovery

iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.

IBIO-600

IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment.

Cardiopulmonary Expansion

The pipeline also includes a bispecific antibody program for pulmonary hypertension associated with heart failure with preserved ejection fraction.

Cardiometabolic Pipeline

iBio is building a portfolio of long-acting antibody therapies for obesity and related cardiometabolic diseases, led clinically by IBIO-600 and preclinically by IBIO-610.

Future catalysts

  • IND-equivalent filing for IBIO-610 by the end of 2026.
  • Initiation of first-in-human development for IBIO-610 in the first half of 2027.
  • Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.
  • Initiation of the multiple-ascending-dose portion of the IBIO-600 Phase 1 study in the first quarter of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Ibio Inc (IBIO)?

Ibio Inc (IBIO) most recently closed at 0.80 USD, a -5.55% move versus the previous session.

What is the market cap of Ibio Inc (IBIO)?

Ibio Inc currently has a market capitalization of 87.4M USD on BioPharmSignal.

What does Ibio Inc do?

AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary Expansion The pipeline...

On which exchange is IBIO stock listed?

Ibio Inc (IBIO) is associated with AMEX, United States, Biopharma.

What is IBIO-600?

Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.

Which conditions is Ibio Inc targeting with IBIO-600?

Ibio Inc is associated with metabolic disease, obesity based on its company overview and current catalyst commentary.

How does Ibio Inc describe recent progress with IBIO-600?

Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.

What is IBIO-610?

Cardiometabolic Pipeline iBio is building a portfolio of long-acting antibody therapies for obesity and related cardiometabolic diseases, led clinically by IBIO-600 and preclinically by IBIO-610.